A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinib.
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Masitinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 15 Jun 2017 This trial has been suspended in Germany.
- 06 Dec 2014 Status changed from discontinued to recruiting, according to United Kingdom Clinical Research Network record.
- 30 Apr 2014 New source identified and integrated (M.D. Anderson Cancer Center).